Clinical trial · Interventional
Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)
NCT00142181CI-TRIAL-00008734completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety and effects (good or bad) of Campath-1H antibody in the treatment of lymphoplasmacytic lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoplasmacytic Lymphoma | Lymphoplasmacytic Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Waldenstrom's Macroglobulinemia | Waldenstrom Macroglobulinemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Campath-1H | Drug | Alemtuzumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Campath-1H
- description
- 30 mg IV three times a week, 6-12 weeks.
- interventionNames
- Drug: Campath-1H
Primary outcomes (1)
- measure
- To determine the effectiveness of Campath-1H in treating patients with Waldenstrom's macroglobulinemia.
- timeFrame
- 2 years
Secondary outcomes (1)
- measure
- To determine the safety of Campath-1H.
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of lymphoplasmacytic lymphoma including patients with Waldenstrom's macroglobulinemia * Adequate organ function: ANC \> 500/ul; PLT \> 25,000/ul; serum creatinine \< 2.5; serum total bilirubin and SGOT \< 2.5 times the upper normal limit. * Age greater than 18 years * Life expectancy of 6 months or greater * ECOG performance status of 0-2 Exclusion Criteria: * Chemotherapy, steroid therapy, or radiation therapy within 21 days of study entry. * Prior Campath-1H or monoclonal antibody therapy within 3 months of study entry. * Pregnant women * Serious co-morbid disease, uncontrolled bacterial, fungal, or viral infection.
References
Publications (1)
- RESULTTreon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011 Jul 14;118(2):276-81. doi: 10.1182/blood-2011-02-338558. Epub 2011 May 12. PMID 21566092